Ridgeway

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) investors should take a wait and see approach, an analyst said on Monday. According to Scotiabank's Alan Ridgeway, anyone on the fence should "wait and see how the next few months play out." Ridgeway holds a Sector Perform and a $42 price target on the...